ADMA Biologics, Inc. (ADMA) Stock Forecast
ADMA analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.25 / 5 from 4 analysts
- Price target
- $17.00 average of analyst targets
- Upside to target
- +59.2% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $0.19
- 52-week range
- $7.60 – $20.38
ADMA analyst ratings
4 analystsNumber of analysts at each rating.
ADMA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ADMA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.20 | $0.19 | $0.20 | $0.16 | +23.7% | 3 |
| Current fiscal year (2026) | $0.80 | $0.77 | $0.83 | $0.66 | +21.3% | 3 |
| Next fiscal year (2027) | $0.94 | $0.81 | $1.03 | $0.80 | +18.4% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ADMA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $138.1M | $136.8M | $139.8M | +2.9% | 3 |
| Current fiscal year (2026) | $535.3M | $530.6M | $543.0M | +4.9% | 3 |
| Next fiscal year (2027) | $629.5M | $599.9M | $671.7M | +17.6% | 3 |
ADMA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ADMA revenue: reported and forecast
ADMA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | 0.0% | 0 up · 3 down |
| Current fiscal year (2026) | $0.80 | $0.80 | $0.80 | $0.80 | $0.80 | 0.0% | 0 up · 3 down |
| Next fiscal year (2027) | $0.98 | $0.98 | $0.94 | $0.94 | $0.94 | −4.2% | 0 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ADMA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ADMA beat in 9 of 12.
What analysts expect from ADMA
4 analysts cover ADMA Biologics; their consensus rating is buy (4.25 on a 1–5 scale, where 5 is a strong buy). The average price target is $17.00, 59.2% above the latest close of $10.68. Analysts expect earnings of $0.80 per share for 2026, +21.3% from a year earlier. For 2027 the average estimate is $0.94 per share on revenue of $629.5 million. ADMA Biologics beat the EPS estimate in 9 of the last 12 quarters.
Related: ADMA income statement, ADMA key metrics, ADMA chart. See the ADMA stock overview for the latest quote and news.
ADMA forecast FAQ
What is ADMA Biologics's price target?
The average analyst price target for ADMA Biologics is $17.00, 59.2% above the latest close of $10.68.
Is ADMA Biologics a buy, hold or sell?
Of 4 analysts covering ADMA Biologics, 2 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is ADMA Biologics's EPS forecast?
Analysts forecast $0.80 per share for 2026 (range $0.77 to $0.83); for 2027 the estimate is $0.94.
What is ADMA Biologics's revenue forecast?
The average revenue estimate for 2026 is $535.3 million, growth of 4.9%; for 2027 it is $629.5 million.
When does ADMA Biologics report earnings?
ADMA Biologics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $0.19.
Does ADMA Biologics usually beat earnings estimates?
ADMA Biologics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.